

# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## Health Technology Evaluation

### Equality impact assessment – Scoping

#### Evinacumab for treating homozygous familial hypercholesterolaemia in people aged 12 and over [ID2704]

The impact on equality has been assessed during this evaluation according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

Yes, the company noted that lomitapide (a possible comparator) is not indicated in people aged <18 years. However evinacumab (the intervention), which can be used in people ≥12 years. Therefore, there is a potential equality issue for people aged 12-17 years.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

Age is a protected characteristic, so committee will consider whether its recommendations could have a different impact on people aged 12-17 vs aged 18 and above.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

The scope has been updated to include 12-17 year olds as a sub-group. The comparators section has also been updated to reflect that the comparators vary by age group. The committee will consider whether its recommendations could have a different impact on people protected by the equality legislation than on the wider population.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the stakeholder list been made?

N/A

**Approved by Associate Director (name):** .....Jasdeep Hayre

**Date:** 14 March 2023